These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8241508)

  • 1. Plasma dermatan sulfate proteoglycan in a patient on chronic hemodialysis.
    Delorme MA; Saeed N; Sevcik A; Mitchell L; Berry L; Johnston M; Andrew M
    Blood; 1993 Dec; 82(11):3380-5. PubMed ID: 8241508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus.
    Andrew M; Mitchell L; Berry L; Paes B; Delorme M; Ofosu F; Burrows R; Khambalia B
    J Clin Invest; 1992 Jan; 89(1):321-6. PubMed ID: 1729278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.
    Ofosu FA; Modi GJ; Smith LM; Cerskus AL; Hirsh J; Blajchman MA
    Blood; 1984 Sep; 64(3):742-7. PubMed ID: 6235872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
    Ofosu FA
    Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist.
    Buchanan MR; Brister SJ
    Thromb Res; 2000 Sep; 99(6):603-12. PubMed ID: 10974347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simple method to measure dermatan sulfate at sub-microgram concentrations in plasma.
    Dupouy D; Sié P; Dol F; Boneu B
    Thromb Haemost; 1988 Oct; 60(2):236-9. PubMed ID: 3217919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating dermatan sulfate and heparan sulfate/heparin proteoglycans in children undergoing liver transplantation.
    Mitchell L; Superina R; Delorme M; Vegh P; Berry L; Hoogendoorn H; Andrew M
    Thromb Haemost; 1995 Sep; 74(3):859-63. PubMed ID: 8571311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
    Cosmi B; Fredenburgh JC; Rischke J; Hirsh J; Young E; Weitz JI
    Circulation; 1997 Jan; 95(1):118-24. PubMed ID: 8994426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides.
    Ofosu FA; Modi GJ; Hirsh J; Buchanan MR; Blajchman MA
    Ann N Y Acad Sci; 1986; 485():41-55. PubMed ID: 2436525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma anticoagulant mechanisms of heparin, heparan sulfate, and dermatan sulfate.
    Ofosu FA; Buchanan MR; Anvari N; Smith LM; Blajchman MA
    Ann N Y Acad Sci; 1989; 556():123-31. PubMed ID: 2525356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant dermatan sulfate proteoglycan (decorin) in the term human placenta.
    Delorme MA; Xu L; Berry L; Mitchell L; Andrew M
    Thromb Res; 1998 May; 90(4):147-53. PubMed ID: 9692613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial characterization of heparan and dermatan sulfate proteoglycans synthesized by normal rat glomeruli.
    Klein DJ; Brown DM; Oegema TR
    J Biol Chem; 1986 Dec; 261(35):16636-52. PubMed ID: 2946688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate.
    Cosmi B; Agnelli G; Young E; Hirsh J; Weitz J
    Thromb Haemost; 1993 Sep; 70(3):443-7. PubMed ID: 8259546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells.
    McGuire EA; Tollefsen DM
    J Biol Chem; 1987 Jan; 262(1):169-75. PubMed ID: 3793724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemostatic properties and serum lipoprotein binding of a heparan sulfate proteoglycan from bovine aorta.
    Vijayagopal P; Srinivasan SR; Radhakrishnamurthy B; Berenson GS
    Biochim Biophys Acta; 1983 Jul; 758(1):70-83. PubMed ID: 6222769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans.
    Cosmi B; Cini M; Legnani C; Pancani C; Calanni F; Coccheri S
    Thromb Res; 2003 Mar; 109(5-6):333-9. PubMed ID: 12818259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different glycoforms of human thrombomodulin. Their glycosaminoglycan-dependent modulatory effects on thrombin inactivation by heparin cofactor II and antithrombin III.
    Koyama T; Parkinson JF; Sié P; Bang NU; Müller-Berghaus G; Preissner KT
    Eur J Biochem; 1991 Jun; 198(3):563-70. PubMed ID: 1646716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.
    Okwusidi JI; Anvari N; Kulczycky M; Blajchman MA; Buchanan MR; Ofosu FA
    J Lab Clin Med; 1991 May; 117(5):359-64. PubMed ID: 2019790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assay of dermatan sulfate cofactor (heparin cofactor II) activity in human plasma.
    Abildgaard U; Larsen ML
    Thromb Res; 1984 Aug; 35(3):257-66. PubMed ID: 6547786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant dermatan sulfate is a potent activator of heparin cofactor II-dependent inhibition of thrombin.
    Tykesson E; Maccarana M; Thorsson H; Liu J; Malmström A; Ellervik U; Westergren-Thorsson G
    Glycobiology; 2019 Jun; 29(6):446-451. PubMed ID: 30869126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.